Patents by Inventor Xiong Cai

Xiong Cai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FORMULATION OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY
    Publication number: 20120122881
    Abstract: The present invention relates to a composition comprising an inclusion complex of a cyclodextrin and quinazoline containing zinc-binding moiety based derivatives. The cyclodextrin is preferable a ?-cyclodextrin or a derivative thereof. The quinazolines have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR-TK related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.
    Type: Application
    Filed: January 17, 2012
    Publication date: May 17, 2012
    Inventors: Xiong Cai, Changgeng Qian, Haixiao Zhai, Rudi Bao
  • PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY
    Publication number: 20120088764
    Abstract: The instant application relates to deazapurines, thienopyrimidines and furopyrimidines with zinc-binding moiety based derivatives and their use in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.
    Type: Application
    Filed: April 1, 2011
    Publication date: April 12, 2012
    Inventors: Xiong Cai, Haixiao Zhai, Chengjung Lai, Changgeng Qian
  • Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety
    Patent number: 8119616
    Abstract: The present invention relates to a composition comprising an inclusion complex of a cyclodextrin and quinazoline containing zinc-binding moiety based derivatives. The cyclodextrin is preferable a ?-cyclodextrin or a derivative thereof. The quinazolines have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR-TK related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.
    Type: Grant
    Filed: September 10, 2008
    Date of Patent: February 21, 2012
    Assignee: Curis, Inc.
    Inventors: Xiong Cai, Changgeng Qian, Haixiao Zhai, Rudi Bao
  • QUINAZOLINE BASED EGFR INHIBITORS
    Publication number: 20110295004
    Abstract: The present invention relates to quinazoline containing zinc-binding moiety based derivatives of formula I that have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR-TK related diseases and disorders such as cancer.
    Type: Application
    Filed: June 8, 2011
    Publication date: December 1, 2011
    Inventors: Changgeng Qian, Xiong Cai
  • Substituted 2-Aminoacetamides and the Use Thereof
    Publication number: 20110269785
    Abstract: The invention is directed to substituted 2-aminoacetamides represented by formula (II): and to pharmaceutically acceptable salts and prodrugs thereof, wherein the substituents are defined herein. The invention is also directed to the use of substituted 2-aminoacetamides in methods for the treatment of neuronal damage following global and focal ischemia, and for the treatment, prevention or amelioration of pain, anxiety, or manic depression, as anticonvulsants, as antimanic depressants, as local anesthetics, as antiarrhythmics and for the treatment or prevention of diabetic neuropathy.
    Type: Application
    Filed: January 7, 2011
    Publication date: November 3, 2011
    Applicant: Purdue Neuroscience Company
    Inventors: Nancy C. Lan, Yan Wang, Sui Xiong Cai
  • SUBSTITUTED 2-INDOLINONE AS PTK INHIBITORS CONTAINING A ZINC BINDING MOIETY
    Publication number: 20110190366
    Abstract: The present invention relates to substituted 2-indolinone containing zinc-binding moiety based derivatives that have enhanced or unique properties as inhibitors of protein tyrosine kinase (PTK) receptors and their use in the treatment of PTK related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.
    Type: Application
    Filed: March 28, 2011
    Publication date: August 4, 2011
    Inventors: Xiong Cai, Changgeng Qian, Stephen Gould
  • 4-arylamin-or-4-heteroarylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof
    Patent number: 7989462
    Abstract: Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Grant
    Filed: July 3, 2007
    Date of Patent: August 2, 2011
    Assignee: Myrexis, Inc.
    Inventors: Sui Xiong Cai, Mark B. Anderson, Adam Willardsen, Nilantha Sudath Sirisoma, Hong Zhang, Kazuyuki Suzuki
  • TYROSINE KINASE INHIBITORS CONTAINING A ZINC BINDING MOIETY
    Publication number: 20110178095
    Abstract: The present invention relates to tyrosine kinase inhibitors that contain a zinc-binding moiety and their use in the treatment of tyrosine related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.
    Type: Application
    Filed: January 20, 2011
    Publication date: July 21, 2011
    Inventors: Xiong Cai, Changgeng Qian, Stephen Gould, Haixiao Zhai
  • Quinazoline based EGFR inhibitors
    Patent number: 7977347
    Abstract: The present invention relates to quinazoline containing zinc-binding moiety based derivatives of formula I that have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR-TK related diseases and disorders such as cancer.
    Type: Grant
    Filed: September 10, 2007
    Date of Patent: July 12, 2011
    Assignee: Curis, Inc.
    Inventors: Changgeng Qian, Xiong Cai
  • Substituted 4-aryl-chromene as activator of caspases and inducer of apoptosis and as antivascular agent and the use thereof
    Patent number: 7968595
    Abstract: The present invention is directed to a substituted 4H-chromene represented by the Formula 1R, substantially free from the corresponding (S)-stereoisomer: The present invention also relates to the discovery that compound 1R, substantially free from the corresponding (S)-stereoisomer, is an activator of caspases and inducer of apoptosis, as well as an antivascular agent. Therefore, compound 1R, substantially free from the corresponding (S)-stereoisomer, can be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs. Compound 1R, substantially free from the corresponding (S)-stereoisomer, also can be used for the treatment of diseases due to overgrowth of vasculature, such as solid tumors and ocular neovascularization.
    Type: Grant
    Filed: July 6, 2007
    Date of Patent: June 28, 2011
    Assignee: Cytovia, Inc.
    Inventors: Sui Xiong Cai, John A. Drewe, Shailaja Kasibhatla, William D. Kemnitzer, Ben Y. Tseng, Charles Blais, Denis Labrecque, Henriette Gourdeau
  • Substituted 2-indolinone as PTK inhibitors containing a zinc binding moiety
    Patent number: 7928136
    Abstract: The present invention relates to substituted 2-indolinone containing zinc-binding moiety based derivatives that have enhanced or unique properties as inhibitors of protein tyrosine kinase (PTK) receptors and their use in the treatment of PTK related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.
    Type: Grant
    Filed: September 10, 2007
    Date of Patent: April 19, 2011
    Assignee: Curis, Inc.
    Inventors: Xiong Cai, Changgeng Qian, Stephen Gould
  • TARTRATE SALTS OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY
    Publication number: 20110053963
    Abstract: The present invention relates to tartrate salts of quinazoline containing zinc-binding moiety based derivatives of Formula II, below. These compounds are inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and may further act as HDAC inhibitors. The invention further relates to the use of these tartrate salts in the treatment of EGFR-TK related diseases and disorders such as cancer.
    Type: Application
    Filed: November 8, 2010
    Publication date: March 3, 2011
    Inventors: Xiong Cai, Changgeng Qian, Haixiao Zhai
  • Tyrosine kinase inhibitors containing a zinc binding moiety
    Patent number: 7888361
    Abstract: The present invention relates to tyrosine kinase inhibitors that contain a zinc-binding moiety and their use in the treatment of tyrosine related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.
    Type: Grant
    Filed: September 10, 2007
    Date of Patent: February 15, 2011
    Assignee: Curis, Inc.
    Inventors: Xiong Cai, Changgeng Qian, Stephen Gould, Haixiao Zhai
  • Substituted 2-aminoacetamides and the use thereof
    Patent number: 7872127
    Abstract: The invention is directed to substituted 2-aminoacetamides represented by formula (II): and to pharmaceutically acceptable salts and prodrugs thereof, wherein the substituents are defined herein. The invention is also directed to the use of substituted 2-aminoacetamides in methods for the treatment of neuronal damage following global and focal ischemia, and for the treatment, prevention or amelioration of pain, as anticonvulsants, as antimanic depressants, as local anesthetics, as antiarrhythmics and for the treatment or prevention of diabetic neuropathy.
    Type: Grant
    Filed: May 28, 2009
    Date of Patent: January 18, 2011
    Assignee: Purdue Neuroscience Company
    Inventors: Nancy C. Lan, Yan Wang, Sui Xiong Cai
  • Tartrate salts of quinazoline based EGFR inhibitors containing a zinc binding moiety
    Patent number: 7846938
    Abstract: The present invention relates to tartrate salts of quinazoline containing zinc-binding moiety based derivatives of Formula II, below. These compounds are inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and may further act as HDAC inhibitors. The invention further relates to the use of these tartrate salts in the treatment of EGFR-TK related diseases and disorders such as cancer.
    Type: Grant
    Filed: September 10, 2008
    Date of Patent: December 7, 2010
    Assignee: Curis, Inc.
    Inventors: Xiong Cai, Changgeng Qian, Haixiao Zhai
  • Pharmaceutical compounds as activators of caspases and inducers of apoptosis and the use thereof
    Patent number: 7842805
    Abstract: Disclosed are 1-arylamino-phthalazines, 4-arylamino-benzo[d][1,2,3]triazines, and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Grant
    Filed: July 3, 2007
    Date of Patent: November 30, 2010
    Assignees: Myrexis, Inc., EpiCept Corporation
    Inventors: Sui Xiong Cai, Mark B. Anderson, Adam Willardsen, Songchun Jiang, Robert J. Halter, Rachel Slade, Yevgeniya Klimova
  • PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY
    Publication number: 20100222343
    Abstract: The instant application relates to deazapurines, thienopyrimidines and furopyrimidines with zinc-binding moiety based derivatives and their use in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.
    Type: Application
    Filed: January 8, 2010
    Publication date: September 2, 2010
    Inventors: Xiong Cai, Haixiao Zhai, Cheng-Jung Lai, Changgeng Qian
  • FUSED AMINO PYRIDINES FOR THE TREATMENT OF BRAIN TUMORS
    Publication number: 20100184801
    Abstract: The present invention relates to the use of compounds with fused amino pyridine core for the treatment of malignancies associated with brain and lung. The oral administration of compounds of the instant application results in effective brain penetration and provides for non-intrusive treatment of brain and lung tumors.
    Type: Application
    Filed: January 15, 2010
    Publication date: July 22, 2010
    Inventors: Xiong Cai, Changgeng Qian
  • 3-aryl-6-aryl-[ 1,2,4]triazolo[3,4-][1,3,4]thiadiazoles and related compounds as activators of caspases and inducers of apoptosis and the use thereof
    Patent number: 7732468
    Abstract: Disclosed are 3-aryl-6-aryl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazoles and related compounds thereof, represented by the Formula I: wherein Ar1, Ar2, and X are defined herein. The present invention relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Grant
    Filed: November 15, 2007
    Date of Patent: June 8, 2010
    Assignee: Cytovia, Inc.
    Inventors: Sui Xiong Cai, John A. Drewe, Nilantha Sudath Sirisoma, Han-Zhong Zhang
  • Derivatives of gambogic acid and analogs as activators of caspases and inducers of apoptosis
    Patent number: 7622497
    Abstract: The present invention is directed to novel derivatives of gambogic acid and analogs thereof. The present invention also relates to the discovery that novel derivatives of gambogic acid are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention can be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Grant
    Filed: December 17, 2004
    Date of Patent: November 24, 2009
    Assignee: Cytovia, Inc.
    Inventors: Sui Xiong Cai, Songchun Jiang, Han-Zhong Zhang